IR Banner

Press Releases

Date Title and Summary Additional Format
Mar 18, 2020
NewLink Genetics Stockholders Approve Merger with Lumos Pharma
- Combined company, Lumos Pharma, Inc. , to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess
PDF Version
Feb 28, 2020
NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Special Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma AMES, Iowa , Feb. 28, 2020 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31,
PDF Version
Displaying 111 - 112 of 112
Email Alerts Subscription
Download Library
Print
Share
Search Investors